INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Pharmaceuticals Appoints Michael D. Kishbauch Chief Executive Officer
Achillion Secures $10.4 Million Financing
View HTML
Toggle Summary Achillion Pharmaceuticals Appoints Gautam Shah, Ph.D., Vice President, Regulatory Affairs
Achillion Pharmaceuticals Appoints Gautam Shah, Ph.D., Vice President, Regulatory Affairs Achillion Pharmaceuticals Appoints Gautam Shah, Ph.D., Vice President, Regulatory Affairs NEW HAVEN, Conn. October 13, 2004 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of
View HTML
Toggle Summary Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds
Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds Foster City, CA and New Haven, CT, November 29, 2004
View HTML
Toggle Summary Achillion Pharmaceuticals Announces Executive Promotions
Achillion Pharmaceuticals Announces Executive Promotions Achillion Pharmaceuticals Announces Executive Promotions New Haven, CT, March 23, 2005 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases,
View HTML
Toggle Summary Achillion Announces Receipt of SBIR Grant from National Institutes of Health for New Area of HIV Research
Company to Optimize Novel Capsid Assembly Inhibitor
View HTML
Toggle Summary Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C
Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C Foster City, CA and New Haven, CT, August 15, 2005 —Gilead
View HTML
Toggle Summary Achillion Pharmaceuticals to Provide Update on Infectious Disease Programs at UBS Global Life Sciences Conference
Achillion Pharmaceuticals to Provide Update on Infectious Disease Programs at UBS Global Life Sciences Conference Achillion Pharmaceuticals to Provide Update on Infectious Disease Programs at UBS Global Life Sciences Conference New Haven, CT, September 22, 2005 — Achillion Pharmaceuticals, Inc., a
View HTML
Toggle Summary Achillion Pharmaceuticals to Present at Two Upcoming Investor Conferences
Achillion Pharmaceuticals to Present at Two Upcoming Investor Conferences Achillion Pharmaceuticals to Present at Two Upcoming Investor Conferences New Haven, CT, November 4, 2005 — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most
View HTML
Toggle Summary Achillion Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Achillion Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering Achillion Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering New Haven, Conn, April 3, 2006 — Achillion Pharmaceuticals, Inc., announced today that it has filed a registration
View HTML
Toggle Summary Achillion Pharmaceuticals Announces Pricing of Its Initial Public Offering
New Haven, Conn., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the pricing of its initial public offering of 4,500,000 shares of its common stock at $11.50 per share, before underwriting discounts and commissions.
View HTML